Does Combination Therapy With SGLT2 Inhibitors and Renin-Angiotensin System Blockers Lead to Greater Reduction in Cardiorenal Events Among Patients With Type 2 Diabetes?

ABSTRACT:

SUBMITTER: Zhao LM 

PROVIDER: S-EPMC8131654 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature